6/28/23, 11:44 PM OCEAN(a)-DOSE (olpasiran 225 mg every 24 weeks) Pathway Feedback Search Clinical Topics Home Studies OCEAN(a)-DOSE (olpasiran 225 mg every 24 weeks) OCEAN(a)-DOSE (olpasiran 225 mg every 24 weeks) Disease Disease Disease Acute ischemic stroke Coronary artery disease Dyslipidem Trial question What is the role of olpasiran in patients with established ASCVD? Study design Multi-center Double blinded RCT Population Characteristics of study participants 37.0% female N = 109 63.0% male 109 patients (40 female, 69 male) Inclusion criteria: patients with established ASCVD and a lipoprotein(a) concentration > 150 nmol/L Key exclusion criteria: severe renal dysfunction or active liver disease Interventions N=55 olpasiran (at a dose of 225 mg every 24 week) N=54 placebo (matching placebo every 12 week) Primary outcome https://web.pathway.md/studies/recBLvbMi0q2D58wS 1/2 6/28/23, 11:44 PM OCEAN(a)-DOSE (olpasiran 225 mg every 24 weeks) Pathway Significant increase in percent reduction in lipoprotein(a) concentration at week 36 (96.9% vs. -3.6%; AD 100.5%, 95% CI 95.8 to 105.2) Secondary outcomes Significant increase in percent reduction in low-density lipoprotein cholesterol concentration at week 36 (18.5% vs. -6.3%; AD 24.8%, 95% CI 13 to 36.5) Significant increase in percent reduction in ApoB concentration at week 36 (11.4% vs. -7.4%; AD 18.8%, 95% CI 11.2 to 26.3) Safety outcomes No significant difference in adverse and serious adverse events. Conclusion In patients with established ASCVD and a lipoprotein(a) concentration > 150 nmol/L, olpasiran was superior to placebo with respect to percent reduction in lipoprotein(a) concentration at week 36. Reference Michelle L O'Donoghue, Robert S Rosenson, Baris Gencer et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022 Nov 17;387(20):1855-1864. Open reference URL https://web.pathway.md/studies/recBLvbMi0q2D58wS 2/2